Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AB Science SA, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
AB Science Raises USD20.5 Million in Private Placement of Shares 11
AB Science Raises USD16.2 Million in Private Placement of Shares 12
AB Science Raises USD8 Million in Public Offering of Shares 13
AB Science Raises USD13.5 Million in Private Placement of Shares 14
Debt Offering 16
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 16
AB Science SA – Key Competitors 17
AB Science SA – Key Employees 18
AB Science SA – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Oct 01, 2018: AB Science reports its revenues for the first half of 2018 20
Apr 30, 2018: AB Science reports its annual financials as of 31 December 2017 and provides an update on its activities 24
Aug 31, 2017: AB Science: Revenue Report For First Half of 30 June 2017 30
Aug 31, 2017: AB Science reports its revenue for the first half of 2017 34
May 01, 2017: AB Science Reports its Annual Financials as of 31 December 2016 and Provides an Update on its Activities 40
Product News 47
09/28/2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017 47
09/14/2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment 50
05/28/2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis 51
05/18/2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) 52
05/17/2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 53
04/19/2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis 55
03/22/2018: EPFL: Attacking lymphoma at the source 56
03/20/2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis 57
Clinical Trials 59
Jan 04, 2018: AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to increase the sample size 59
Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine 60
Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight 62
Jun 22, 2017: AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association 64
May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting 66
May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards 68
Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 70
Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 71
Mar 06, 2017: AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma 72
Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis 73
Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
AB Science SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Deals By Therapy Area, 2012 to YTD 2018 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AB Science Raises USD20.5 Million in Private Placement of Shares 11
AB Science Raises USD16.2 Million in Private Placement of Shares 12
AB Science Raises USD8 Million in Public Offering of Shares 13
AB Science Raises USD13.5 Million in Private Placement of Shares 14
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 16
AB Science SA, Key Competitors 17
AB Science SA, Key Employees 18
AB Science SA, Subsidiaries 19
List of Figures
AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
